-
Mashup Score: 0
The Investor Relations website contains information about AbbVie’s business for stockholders, potential investors, and financial analysts.
Source: investors.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 7
The Investor Relations website contains information about AbbVie’s business for stockholders, potential investors, and financial analysts.
Source: investors.abbvie.comCategories: General Medicine News, PayerTweet-
Join our #investor call this Friday, January 31, at 8am CT, where we’ll share our full-year and Q4 2024 #FinancialResults. https://t.co/ncZhn9KfSb #earnings $ABBV https://t.co/WaYzvlKFGU
-
-
Mashup Score: 9AbbVie Completes Acquisition of Nimble Therapeutics - 8 day(s) ago
Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie’s pipeline and R&D capabilities…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
Nimble Therapeutics is now part of AbbVie. This #acquisition expands our pipeline with a novel approach in #psoriasis and enhances our R&D capabilities with a new technology: https://t.co/WIHUNWsIo8 $ABBV https://t.co/hvDukW9Akl
-
-
Mashup Score: 13
Proposed acquisition adds Nimble’s lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis, and a pipeline of other novel oral peptide assets across…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
JUST IN: We’ve signed a definitive agreement to acquire Nimble Therapeutics to further strengthen our #immunology pipeline, with a goal of developing novel medicines for people living with #autoimmune diseases. Learn more: https://t.co/oeT8ji285B https://t.co/xk6K0E5tWW
-
-
Mashup Score: 3Oncology Research & Treatment - 2 month(s) ago
AbbVie advances cancer research and treatment to elevate the standard of care for blood cancer patients, and in the future other cancers like solid tumors.
Source: www.abbvie.comCategories: General Medicine News, PayerTweet-
Patients with follicular #lymphoma often relapse or become refractory after initial therapy, and people in this setting face limited treatment options with few readily available medicines. Learn how we’re working to expand treatment options: https://t.co/1eArOLapRN https://t.co/jPWZgypuGN
-
-
Mashup Score: 0Can we find cures faster? - 2 month(s) ago
Learn how AbbVie researchers find and advance ideas that have the potential to cure.
Source: www.abbvie.comCategories: General Medicine News, PayerTweet-
What does curing a disease look like? The short answer: it varies. See what our #researchers look for on the pathway to a #cure: https://t.co/loYsNugO3s https://t.co/g0OLKFxlzm
-
-
Mashup Score: 8AbbVie Completes Acquisition of Aliada Therapeutics - 2 month(s) ago
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer’s disease, ALIA-1758, and novel blood-brain barrier (BBB)-crossing technology to strengthen neuroscience pipeline…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
NEWS: @aliadatx is now part of AbbVie. This #acquisition expands our neuroscience pipeline with an investigational therapy in #Alzheimers disease and a novel blood-brain barrier-crossing technology. Read more: https://t.co/A2LWpGAHaL $ABBV https://t.co/2GAIbZ8BQK
-
-
Mashup Score: 8
Data presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) NORTH CHICAGO, Ill., Dec. 9, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced new…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
NEWS: We are presenting new data at #ASH24 evaluating our investigational treatment for diffuse large B-cell #lymphoma patients, in collaboration with @Genmab. Explore: https://t.co/72DgcZdeUj https://t.co/kwF7Rs4iow
-
-
Mashup Score: 4AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease - 2 month(s) ago
Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-2 flexible-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
JUST IN: Today, we announced results from a Phase 3 trial of our investigational #ParkinsonsDisease treatment. Learn more: https://t.co/JrCHyEMXbe https://t.co/fVO4gSBU6A
-
-
Mashup Score: 9
Data presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) NORTH CHICAGO, Ill., Dec. 7, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced updated…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
JUST IN: We’re sharing new data at #ASH24 evaluating our investigational treatment for patients with relapsed or refractory follicular #lymphoma, in collaboration with @Genmab. Read more: https://t.co/FE24Cp2XrQ https://t.co/zKaj1nbrcx
-
Reminder: Join us tomorrow at 8am CT as we share our full-year and Q4 2024 #FinancialResults. https://t.co/n0FXg4AhBC #earnings $ABBV https://t.co/MoME8vIpCo